275 related articles for article (PubMed ID: 36414219)
21. Thrombopoietin participates in platelet activation in COVID-19 patients.
Lupia E; Capuano M; Vizio B; Schiavello M; Bosco O; Gelardi M; Favale E; Pivetta E; Morello F; Husain S; Keshavjee S; Del Sorbo L; Montrucchio G
EBioMedicine; 2022 Nov; 85():104305. PubMed ID: 36242922
[TBL] [Abstract][Full Text] [Related]
22. Immunothrombosis and Complement Activation Contribute to Disease Severity and Adverse Outcome in COVID-19.
Ruggeri T; De Wit Y; Schärz N; van Mierlo G; Angelillo-Scherrer A; Brodard J; Schefold JC; Hirzel C; Jongerius I; Zeerleder S
J Innate Immun; 2023; 15(1):850-864. PubMed ID: 37939687
[TBL] [Abstract][Full Text] [Related]
23. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients.
Holter JC; Pischke SE; de Boer E; Lind A; Jenum S; Holten AR; Tonby K; Barratt-Due A; Sokolova M; Schjalm C; Chaban V; Kolderup A; Tran T; Tollefsrud Gjølberg T; Skeie LG; Hesstvedt L; Ormåsen V; Fevang B; Austad C; Müller KE; Fladeby C; Holberg-Petersen M; Halvorsen B; Müller F; Aukrust P; Dudman S; Ueland T; Andersen JT; Lund-Johansen F; Heggelund L; Dyrhol-Riise AM; Mollnes TE
Proc Natl Acad Sci U S A; 2020 Oct; 117(40):25018-25025. PubMed ID: 32943538
[TBL] [Abstract][Full Text] [Related]
24. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
25. Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China.
Wu H; Zhu H; Yuan C; Yao C; Luo W; Shen X; Wang J; Shao J; Xiang Y
JAMA Netw Open; 2020 Jun; 3(6):e2010895. PubMed ID: 32492165
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-6, procalcitonin and neutrophil-to-lymphocyte ratio: Potential immune-inflammatory parameters to identify severe and fatal forms of COVID-19.
Sayah W; Berkane I; Guermache I; Sabri M; Lakhal FZ; Yasmine Rahali S; Djidjeli A; Lamara Mahammed L; Merah F; Belaid B; Berkani L; Lazli NZ; Kheddouci L; Kadi A; Ouali M; Khellafi R; Mekideche D; Kheliouen A; Hamidi RM; Ayoub S; Raaf NB; Derrar F; Gharnaout M; Allam I; Djidjik R
Cytokine; 2021 May; 141():155428. PubMed ID: 33550165
[TBL] [Abstract][Full Text] [Related]
27. Identification of Parameters Representative of Immune Dysfunction in Patients with Severe and Fatal COVID-19 Infection: a Systematic Review and Meta-analysis.
Qin R; He L; Yang Z; Jia N; Chen R; Xie J; Fu W; Chen H; Lin X; Huang R; Luo T; Liu Y; Yao S; Jiang M; Li J
Clin Rev Allergy Immunol; 2023 Feb; 64(1):33-65. PubMed ID: 35040086
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II).
Ye Q; Wang H; Xia X; Zhou C; Liu Z; Xia ZE; Zhang Z; Zhao Y; Yehenala J; Wang S; Zhou G; Hu K; Wu B; Wu CT; Wang S; He Y
Trials; 2020 Jun; 21(1):520. PubMed ID: 32532356
[TBL] [Abstract][Full Text] [Related]
29. Establishing a model for predicting the outcome of COVID-19 based on combination of laboratory tests.
Wang F; Hou H; Wang T; Luo Y; Tang G; Wu S; Zhou H; Sun Z
Travel Med Infect Dis; 2020; 36():101782. PubMed ID: 32526372
[TBL] [Abstract][Full Text] [Related]
30. A disturbed balance between blood complement protective factors (FH, ApoE) and common pathway effectors (C5a, TCC) in acute COVID-19 and during convalesce.
Laudanski K; Okeke T; Siddiq K; Hajj J; Restrepo M; Gullipalli D; Song WC
Sci Rep; 2022 Aug; 12(1):13658. PubMed ID: 35953544
[TBL] [Abstract][Full Text] [Related]
31. Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm.
Kozma GT; Mészáros T; Bakos T; Hennies M; Bencze D; Uzonyi B; Győrffy B; Cedrone E; Dobrovolskaia MA; Józsi M; Szebeni J
Front Immunol; 2021; 12():642860. PubMed ID: 33995361
[TBL] [Abstract][Full Text] [Related]
32. IL-6 at the center of cytokine storm: Circulating inflammation mediators as biomarkers in hospitalized COVID-19 patients.
Elbadawy HM; Khattab A; El-Agamy DS; Eltahir HM; Alhaddad A; Aljohani FD; Almuzaini TM; Abouzied MM; Aldhafiri A
J Clin Lab Anal; 2023 Apr; 37(7):e24881. PubMed ID: 37096731
[TBL] [Abstract][Full Text] [Related]
33. IP-10 and complement activation as friend or foe in COVID-19.
Bunprakob S; Hemachudha P; Ruchisrisarod C; Supharatpariyakorn T; Hemachudha T
Int J Immunopathol Pharmacol; 2022; 36():3946320221096202. PubMed ID: 35531750
[TBL] [Abstract][Full Text] [Related]
34. Inflammatory Markers, Pulmonary Function, and Clinical Symptoms in Acute COVID-19 Among Non-Hospitalized Adolescents and Young Adults.
Lund Berven L; Selvakumar J; Havdal L; Stiansen-Sonerud T; Einvik G; Leegaard TM; Tjade T; Michelsen AE; Mollnes TE; Wyller VBB
Front Immunol; 2022; 13():837288. PubMed ID: 35222429
[TBL] [Abstract][Full Text] [Related]
35. Predictive Role of Cytokine and Adipokine Panel in Hospitalized COVID-19 Patients: Evaluation of Disease Severity, Survival and Lung Sequelae.
Bergantini L; d'Alessandro M; Gangi S; Bianchi F; Cameli P; Perea B; Meocci M; Fabbri G; Marrucci S; Ederbali M; Bargagli E
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629176
[TBL] [Abstract][Full Text] [Related]
36. Circulatory Cytokine Levels as a Predictor of Disease Severity in COVID-19: A Study from Western India.
Bhandari S; Rankawat G; Mathur S; Kumar A; Sahlot R; Jain A
J Assoc Physicians India; 2022 May; 70(5):11-12. PubMed ID: 35598128
[TBL] [Abstract][Full Text] [Related]
37. Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality.
Leatherdale A; Stukas S; Lei V; West HE; Campbell CJ; Hoiland RL; Cooper J; Wellington CL; Sekhon MS; Pryzdial ELG; Conway EM
Med Microbiol Immunol; 2022 Feb; 211(1):37-48. PubMed ID: 35034207
[TBL] [Abstract][Full Text] [Related]
38. Role of Innate and Adaptive Cytokines in the Survival of COVID-19 Patients.
Monserrat J; Gómez-Lahoz A; Ortega MA; Sanz J; Muñoz B; Arévalo-Serrano J; Rodríguez JM; Gasalla JM; Gasulla Ó; Arranz A; Fortuny-Profitós J; Mazaira-Font FA; Teixidó Román M; Martínez-A C; Balomenos D; Asunsolo A; Álvarez-Mon M; On Behalf Of The Covid-Hupa Group
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142255
[TBL] [Abstract][Full Text] [Related]
39. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.
Han H; Ma Q; Li C; Liu R; Zhao L; Wang W; Zhang P; Liu X; Gao G; Liu F; Jiang Y; Cheng X; Zhu C; Xia Y
Emerg Microbes Infect; 2020 Dec; 9(1):1123-1130. PubMed ID: 32475230
[TBL] [Abstract][Full Text] [Related]
40. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
